CA2565944C - Stabilized hyaluronan preparations and related methods - Google Patents
Stabilized hyaluronan preparations and related methods Download PDFInfo
- Publication number
- CA2565944C CA2565944C CA2565944A CA2565944A CA2565944C CA 2565944 C CA2565944 C CA 2565944C CA 2565944 A CA2565944 A CA 2565944A CA 2565944 A CA2565944 A CA 2565944A CA 2565944 C CA2565944 C CA 2565944C
- Authority
- CA
- Canada
- Prior art keywords
- hyaluronan
- polyglycol
- range
- chloride
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 77
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title claims abstract description 74
- 229940099552 hyaluronan Drugs 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 22
- 229920000151 polyglycol Polymers 0.000 claims abstract description 32
- 239000010695 polyglycol Substances 0.000 claims abstract description 32
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 27
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 7
- 239000004327 boric acid Substances 0.000 claims description 7
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 7
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 7
- 150000002978 peroxides Chemical class 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- WLURHQRAUSIQBH-UHFFFAOYSA-N sodium;hexahydrate Chemical compound O.O.O.O.O.O.[Na] WLURHQRAUSIQBH-UHFFFAOYSA-N 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 7
- 206010013774 Dry eye Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010011013 Corneal erosion Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000037309 reepithelialization Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- GPIHAUAAQOAXNW-UHFFFAOYSA-N O.O.O.O.O.O.O.O.O.O.O.O.[Na] Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na] GPIHAUAAQOAXNW-UHFFFAOYSA-N 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100001032 irritation of the eye Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56940704P | 2004-05-07 | 2004-05-07 | |
| US60/569,407 | 2004-05-07 | ||
| PCT/US2005/016271 WO2005110439A2 (en) | 2004-05-07 | 2005-05-09 | Stabilized hyaluronan preparations and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2565944A1 CA2565944A1 (en) | 2005-11-24 |
| CA2565944C true CA2565944C (en) | 2011-07-19 |
Family
ID=35394663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2565944A Expired - Lifetime CA2565944C (en) | 2004-05-07 | 2005-05-09 | Stabilized hyaluronan preparations and related methods |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7544671B2 (enExample) |
| EP (1) | EP1746884A4 (enExample) |
| JP (1) | JP2007536277A (enExample) |
| AU (1) | AU2005244059A1 (enExample) |
| CA (1) | CA2565944C (enExample) |
| MX (1) | MXPA06013056A (enExample) |
| WO (1) | WO2005110439A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070104798A1 (en) | 1999-10-04 | 2007-05-10 | S.K. Pharmaceuticals, Inc. | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |
| FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
| US20070031468A1 (en) * | 2005-08-04 | 2007-02-08 | Endomedix, Inc. | Modified chitosan for vascular embolization |
| US20070031467A1 (en) * | 2005-08-04 | 2007-02-08 | Abrahams John M | Composition and method for vascular embolization |
| TW200733993A (en) * | 2005-11-03 | 2007-09-16 | Reseal Internat Ltd Partnership | Continuously sealing one way valve assembly and fluid delivery system and formulations for use therein |
| US20080075657A1 (en) * | 2006-04-18 | 2008-03-27 | Abrahams John M | Biopolymer system for tissue sealing |
| US20070243130A1 (en) * | 2006-04-18 | 2007-10-18 | Weiliam Chen | Biopolymer system for tissue sealing |
| US7854923B2 (en) * | 2006-04-18 | 2010-12-21 | Endomedix, Inc. | Biopolymer system for tissue sealing |
| US20080124395A1 (en) * | 2006-06-22 | 2008-05-29 | Weiliam Chen | Formulations and devices for treatment or prevention of neural ischemic damage |
| KR20090053892A (ko) | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| DE102006049580A1 (de) * | 2006-10-20 | 2008-04-24 | Rochel, Michael, Dr. med. | Topische Zusammensetzung zur Behandlung von Ekzemen |
| WO2009006130A2 (en) * | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
| US20110195927A1 (en) * | 2008-09-15 | 2011-08-11 | Compositions Comprising Polymers Having Aminio Sugar Unites And Methods Of Making And Using Same | Compositions Comprising Polymers Having Amino Sugar Units and Methods of Making and Using Same |
| WO2010125069A1 (en) * | 2009-04-28 | 2010-11-04 | Pharmasurgics In Sweden Ab | Hyaluronic acid for preventing post surgical adhesions |
| IT1394223B1 (it) | 2009-05-15 | 2012-06-01 | Thea Sas Lab | Kit per la valutazione e la selezione personalizzata di lacrime artificiali |
| US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
| US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
| DE102011077393A1 (de) * | 2011-06-10 | 2012-12-13 | Johannes Reinmüller | Antiinfektives Mittel |
| US8623839B2 (en) * | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| KR101383941B1 (ko) * | 2012-03-09 | 2014-04-10 | 동아에스티 주식회사 | 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법 |
| PT3019177T (pt) | 2013-07-10 | 2020-12-30 | Matrix Biology Inst | Composições de hialuronano de elevada elasticidade e suas utilizações |
| US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
| CN113577097A (zh) | 2015-09-24 | 2021-11-02 | 基质生物研究所 | 高弹性透明质酸组合物及其使用方法 |
| PL3231417T3 (pl) * | 2016-04-15 | 2019-05-31 | Dr Gerhard Mann Chem Pharm Fabrik Gmbh | Odporna na składowanie kompozycja oftalmiczna |
| DE102018124022A1 (de) | 2018-09-28 | 2020-04-02 | Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen | Hyaluronsäurestabilisator |
| US10517988B1 (en) | 2018-11-19 | 2019-12-31 | Endomedix, Inc. | Methods and compositions for achieving hemostasis and stable blood clot formation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4629623A (en) * | 1984-06-11 | 1986-12-16 | Biomatrix, Inc. | Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof |
| JPS6479103A (en) * | 1987-06-09 | 1989-03-24 | Lion Corp | External preparation |
| US5141741A (en) * | 1988-12-09 | 1992-08-25 | Lion Corporation | Anti-sunburn skin-care preparation |
| JPH05170641A (ja) * | 1991-12-25 | 1993-07-09 | Shiseido Co Ltd | 化粧料 |
| JPH09227385A (ja) * | 1996-02-29 | 1997-09-02 | Ofutekusu:Kk | 眼手術用補助剤 |
| JPH1072376A (ja) * | 1996-09-02 | 1998-03-17 | Ofutekusu:Kk | ヒアルロン酸含有点眼水溶液 |
| JPH10290830A (ja) * | 1997-04-18 | 1998-11-04 | Ofutekusu:Kk | 眼手術用補助剤 |
| US6372755B2 (en) * | 1997-07-11 | 2002-04-16 | Toray Industries, Inc. | Stable medicinal compositions containing 4,5-epoxymorphinan derivatives |
| AU778853B2 (en) * | 1999-04-02 | 2004-12-23 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
| JP2001019611A (ja) * | 1999-07-08 | 2001-01-23 | Pola Chem Ind Inc | 皮膚外用組成物 |
| JP2004514778A (ja) * | 2000-11-28 | 2004-05-20 | フォーカル インコーポレーティッド | ポリアルキレングリコール粘度増強性重合製剤 |
| JP2002193815A (ja) * | 2000-12-25 | 2002-07-10 | Ophtecs Corp | 眼手術用角膜乾燥防止点眼剤 |
| FR2825273B1 (fr) * | 2001-05-29 | 2006-11-24 | Oreal | Composition pour le traitement des signes cutanes du vieillissement |
| CA2472188C (en) * | 2002-01-18 | 2011-06-21 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| JP4263456B2 (ja) * | 2002-03-18 | 2009-05-13 | わかもと製薬株式会社 | ヒアルロン酸含有熱ゲル化製剤 |
| US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
| US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
-
2005
- 2005-05-09 AU AU2005244059A patent/AU2005244059A1/en not_active Abandoned
- 2005-05-09 JP JP2007511718A patent/JP2007536277A/ja active Pending
- 2005-05-09 US US11/126,075 patent/US7544671B2/en not_active Expired - Lifetime
- 2005-05-09 WO PCT/US2005/016271 patent/WO2005110439A2/en not_active Ceased
- 2005-05-09 MX MXPA06013056A patent/MXPA06013056A/es unknown
- 2005-05-09 EP EP05747840A patent/EP1746884A4/en not_active Ceased
- 2005-05-09 CA CA2565944A patent/CA2565944C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007536277A (ja) | 2007-12-13 |
| EP1746884A2 (en) | 2007-01-31 |
| WO2005110439A3 (en) | 2006-05-11 |
| WO2005110439A2 (en) | 2005-11-24 |
| EP1746884A4 (en) | 2010-01-13 |
| US20060029571A1 (en) | 2006-02-09 |
| MXPA06013056A (es) | 2007-04-17 |
| AU2005244059A1 (en) | 2005-11-24 |
| CA2565944A1 (en) | 2005-11-24 |
| US7544671B2 (en) | 2009-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2565944C (en) | Stabilized hyaluronan preparations and related methods | |
| US20210128604A1 (en) | Stabilized Glycosaminoglycan Preparations and Related Methods | |
| JP2003528906A (ja) | ドライアイを処置するための方法 | |
| CN104394934A (zh) | 包含至少一种透明质酸及至少一种蔗糖八硫酸酯水溶性盐的在水性介质中的组合物 | |
| CA2737263C (en) | Mucomimetic compositions and uses therefore | |
| CN105705137A (zh) | 获得基于含有以粉末形式添加的利多卡因和碱剂的透明质酸且热灭菌的可注射水凝胶的方法 | |
| US20100022472A1 (en) | Liquid, eye-instillable preparations comprising sodium hyaluronate | |
| US7521434B2 (en) | Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making them | |
| CA3212315A1 (en) | Ophthalmic solutions | |
| EP1128809B1 (en) | Aqueous ophthalmic formulations comprising chitosan | |
| WO2006105384A1 (en) | Composition for treating dry eye and related methods of manufacture and methods of use | |
| WO2020140365A1 (zh) | 一种含有黄原胶的保湿润滑组合物及其应用 | |
| WO2007005421A2 (en) | Long lasting alginate dry eye, related methods of manufacture and methods of use | |
| WO2019097427A1 (en) | Resorbable implantable devices based on crosslinked glycosaminoglycans, and process for the preparation thereof | |
| JPH1143446A (ja) | 水性製剤の増粘剤 | |
| TW200829260A (en) | Method of stimulating the production of mucin in the eye of a patient | |
| JP2020510088A (ja) | 新規な粘弾性溶液及びそのリウマチ学における使用 | |
| CN120424720A (zh) | 眼科用镜的护理组合物及其应用 | |
| KR20170078793A (ko) | 안과용 조성물 | |
| WO2007007076A1 (en) | Contact lens care solution | |
| CN114828903A (zh) | 滑液代用品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |